Circulating Ca 15.3 Levels in Breast Cancer. Our Present Experience

Colomer, Ramon; Ruibal, A; Navarro, M D; Encabo, G; Solé, L.A.; Salvador, L

doi:10.1177/172460088600100206

Cited by 25 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, most of these tumour marker increases were concomitant with benign disease, in particular consistent with previous data (Nicolini et al, 1989;Colomer et al, 1986;Ruibal et al, 1986a, b), hepatic diseases (transient or chronic liver failure, diabetes and/or hepatic steatosis) seem to be the most commonly involved. Thus a very high specificity ranging from 96 to 99% was obtained both when three tumour markers were considered alone and in association (Table I).…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

Nicolini

Colombini²,

Luciani³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

Summary The usefulness of post-operatively serial serum CA15-3 determination with CEA and TPA was evaluated in a group of 285 breast cancer patients. In particular, the CAI 5-3 sensitivity to 'early' diagnosis and monitoring of the response to treatment of breast cancer relapses, was compared with those of the two other markers in order to'define the most suitable association. Moreover, in a group of 169 non relapsed patients with a prolonged follow-up (40±8 months; mean±s.d.) CA15-3 specificity was investigated.During post-operative follow-up in 27 (10%) patients, distant metastases occurred. In most of them, elevated values of one or more tumour markers were the first pathological sign and CA15-3, CEA and TPA sensitivity to 'early' diagnosis of metastases were 46%, 7% and 63% respectively. When each tumour marker was considered in combination, CA15-3-CEA-TPA association showed a higher sensitivity (87%) than both CA15-3-TPA (83%) and the CEA-TPA (70%). Serum CA15-3 increase preceded the certain sign of metastases 2.7 ± 2.6 months (mean ± s.d. In our previous study (Nicolini et al., 1989) we showed that their serial serum determinations with contemporaneous urinary hydroxyproline-creatinine ratio (OHP/Cr) measurement (the latter as a bone tissue marker) provide guidelines for a rational post-operative follow-up of breast cancer patients. In fact, in most patients, high values of these tumour markers were the first sign of relapse; furthermore, they are easily repeatable and harmless examinations. More recently, a new antigenic determinant defined by two monoclonal antibodies (115 D8 and DF3), has been found in blood of patients with breast cancer. Thus, an immunoradiometric assay (IRMA), has been developed with these two MAbs to measure the breast cancer associated antigen 115 D8/DF3 (CA15-3).So far, the collected data also suggest that this tumour marker is not useful for the diagnosis of the primary tumour (Gion et al., 1986;Schmidt-Rhode et al., 1987). Moreover, they indicate that this new marker correlates with the stage of disease and in metastatic patients with the response to treatment (Colomer et al., 1986;Hilkens et al., 1984;Omar et al., 1988).Nevertheless, there are insufficient data to define whether this marker is advisable for use with or in place of the more commonly used markers for the post-operative follow-up of breast cancer patients.In our Center since 1985, all breast cancer patients followed-up with CEA and TPA have also been followed with serial serum CA15-3 determinations.The prolonged period of observation and the large number of patients studied allowed us to evaluate the usefulness of serum CA15-3 measurement in 'early diagnosis' and in the monitoring of response to therapy of breast cancer relapses. Moreover, these findings were compared with those of CEA and TPA to define the most suitable association of these three tumour markers. Materials and methods PatientsSince June 1985 until September 1989, 285 breast cancer patients, aged 29 to 84 years, followed-up post-operatively with se...

show abstract

Section: Discussionsupporting

confidence: 89%

“…Moreover, they indicate that this new marker correlates with the stage of disease and in metastatic patients with the response to treatment (Colomer et al, 1986;Hilkens et al, 1984;Omar et al, 1988).…”

mentioning

confidence: 99%

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

Nicolini

Colombini²,

Luciani³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…These findings are in agreement with pre vious studies which report that percentages of elevated serum concentrations of CA 15.3 [11,[19][20][21][22][23][24] or MCA [E. Bombardieri pers. commun., 1988] increase through stages of disease.…”

Section: Discussionsupporting

confidence: 82%

“…commun., 1988] increase through stages of disease. However, the results are at variance with the previously reported higher percent ages of patients with elevated concentrations of either marker [11,[19][20][21][22][23][24]. A probable rea son for the discrepancy is that lower cutoff values were selected in those reports: 22-31 U/ml for CA 15.3 and 11 U/ml for MCA.…”

Section: Discussioncontrasting

confidence: 56%

Pretreatment Concentrations of Breast Carcinoma Antigen (CA 15.3) and Mucin-Like Carcinoma-Associated Antigen in Patients with Carcinoma of the Breast

Góźdż¹,

Kowalska

Słuszniak³

et al. 1989

Tumor Biol

View full text Add to dashboard Cite

Pretreatment serum concentrations of breast Carcinoma antigen (CA 15.3) and mucin-like carcinoma-associated antigen (MCA) were determined in 129 patients with breast Carcinoma. Concentrations of both markers were within the normal ränge in patients with Stage I disease. Concentrations of CA 15.3 were elevated (> 40 U/ml) in 3, 11 and 48%, those of MCA(> 17 U/ml) in 11, 18 and 52%, and those of one or the other marker in 11,18 and 58% of the patients with Stage II, III and IV disease, respectively. The elevation of either marker roughly paralleled the size of the tumor being normal in the patients with localized Cancer, slightly elevated in a small proportion of the patients with locoregional Cancer, and moderately to markedly elevated in half of the patients with distant metastases. Correlation between serum concentrations of CA 15.3 and MCA was highly significant (p < 0.0001). It is concluded that the markers were equally sensitive and that an elevated serum level was a useful adjunct for Staging, implying systemic disease.

show abstract

“…Since the first description of the immuno assay for breast carcinoma antigen (CA 15-3) [1], several contributions have been made regarding the clinical relevance of the deter mination of CA 15-3 in the follow-up and during treatment of patients with breast can cer [2][3][4][5][6]. Comparative studies with carcinoembryonic antigen (CEA) revealed a greater sensitivity of CA 15-3 over CEA in detecting metastatic breast cancer [7,8].…”

Section: Introductionmentioning

confidence: 99%

Pre-Operative Tumour Marker Levels in Patients with Breast Cancer and Their Prognosis

Dalen¹

1990

Tumor Biol

View full text Add to dashboard Cite

The serum levels of carcino-embryonic antigen, tissue polypeptide antigen (TPA), breast carcinoma antigen 15–3 and mucin-like carcinoma-associated antigen were measured pre-operatively in 99 patients with breast cancer receiving no adjuvant hormonal or chemotherapy and in 64 patients with benign breast tumours. Using the 95th percentile of the marker levels in patients with benign breast tumours as the cut-off level, marker levels in patients with breast cancer were related to prognosis. In the follow-up period of 6–36 months (mean =17.9 months), 20 out of the 99 patients developed metastases. Only 4 out of these 20 patients had elevated pre-operative levels of one or more of the markers. One out of these 4 patients was misclassified having metastatic disease at the time of the operation. On the other hand, in a total of 28 patients the pre-operative levels of one or more markers were noted to be elevated; 26 of the patients remained disease-free at the time of follow-up.

show abstract

Circulating Ca 15.3 Levels in Breast Cancer. Our Present Experience

Cited by 25 publications

References 5 publications

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

Pretreatment Concentrations of Breast Carcinoma Antigen (CA 15.3) and Mucin-Like Carcinoma-Associated Antigen in Patients with Carcinoma of the Breast

Pre-Operative Tumour Marker Levels in Patients with Breast Cancer and Their Prognosis

Contact Info

Product

Resources

About